Corvus Pharmaceuticals, Inc. Operating Lease Liability
Corvus Pharmaceuticals, Inc. (CRVS) had Operating Lease Liability of $354.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2024-11-12
- 2024-09-30: Operating Lease, Liability $354.00K.
- 2024-06-30: Operating Lease, Liability $700.00K.
- 2024-03-31: Operating Lease, Liability $1.04M.
- 2023-12-31: Operating Lease, Liability $1.37M.
| Period end | Operating Lease, Liability |
|---|---|
| 2024-09-30 | $354.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $700.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.04M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.37M 10-Q · filed 2024-11-12 |
| 2022-09-30 | $2.87M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $3.13M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.39M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.65M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $3.88M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $1.78M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $2.05M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $2.31M 10-K · filed 2022-03-10 |
| 2020-09-30 | $2.54M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $2.76M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $2.98M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $3.19M 10-K · filed 2021-03-25 |
| 2019-09-30 | $3.39M 10-Q · filed 2019-10-29 |
| 2019-06-30 | $3.58M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $3.77M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |